High-dose mannose-binding lectin therapy for Ebola virus infection

Ian C. Michelow, Calli Lear, Corinne Scully, Laura I. Prugar, Clifford B. Longley, L. Michael Yantosca, Xin Ji, Marshall Karpel, Matthew Brudner, Kazue Takahashi, Gregory T. Spear, R. Alan B. Ezekowitz, Emmett V. Schmidt, Gene G. Olinger

Research output: Contribution to journalArticlepeer-review


Mannose-binding lectin (MBL) targets diverse microorganisms for phagocytosis and complement-mediated lysis by binding specific surface glycans. Although recombinant human MBL (rhMBL) trials have focused on reconstitution therapy, safety studies have identified no barriers to its use at higher levels. Ebola viruses cause fatal hemorrhagic fevers for which no treatment exists and that are feared as potential biothreat agents. We found that mice whose rhMBL serum concentrations were increased ≥7-fold above average human levels survived otherwise fatal Ebola virus infections and became immune to virus rechallenge. Because Ebola glycoproteins potentially model other glycosylated viruses, rhMBL may offer a novel broadspectrum antiviral approach.

Original languageEnglish (US)
Pages (from-to)175-179
Number of pages5
JournalJournal of Infectious Diseases
Issue number2
StatePublished - Jan 15 2011
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'High-dose mannose-binding lectin therapy for Ebola virus infection'. Together they form a unique fingerprint.

Cite this